Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug450 | Azacitidine Wiki | 0.71 |
| drug118 | ALX148 Wiki | 0.71 |
| drug109 | ADCT-301 Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009190 | Myelodysplastic Syndromes NIH | 0.82 |
| D054437 | Myelodysplastic-Myeloproliferative Diseases NIH | 0.71 |
| D007951 | Leukemia, Myeloid, NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002863 | Myelodysplasia HPO | 0.82 |
| HP:0012324 | Myeloid leukemia HPO | 0.50 |
| HP:0005547 | Myeloproliferative disorder HPO | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004808 | Acute myeloid leukemia HPO | 0.41 |
| HP:0001909 | Leukemia HPO | 0.17 |
| HP:0002664 | Neoplasm HPO | 0.10 |
Navigate: Correlations HPO
There are 2 clinical trials
This Phase 1/2 clinical study will evaluate ALX148 in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).
Description: Number of participants with a DLT
Measure: Phase 1: Dose Limiting Toxicities (DLT) Time: Up to 28 daysDescription: Number of participants achieving a response per International Working Group (IWG) criteria
Measure: Phase 2: Objective response rate (ORR) Time: Approximately 6 monthsThis is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation. ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see how they are responding to the study drug. Patients will be followed for approximately every 12 weeks from the last disease assessment for up to 1 year from completion of therapy. There are risks to this study drug. Some risks include: decrease in certain blood cells, weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system attacks and damages nerves.
Description: Investigator report; efficacy rule
Measure: Morphologic complete response rate of ADCT-301 Time: End of Study, up to 3 yearsDescription: Number of adverse events as measured by self report
Measure: Safety of ADCT-301 Time: up to 12 weeks (84 days) after the last doseAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports